AlphaFold predicted structure
USP27X · A6NNY8

Mean pLDDT
78.2/ 100
Confident
438 residues
Confidence breakdown
- Very high(≥ 90)52%
- Confident(70–90)19%
- Low(50–70)12%
- Very low(< 50)18%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
ubiquitin specific peptidase 27 X-linked
Annotations refreshed 9 hours ago.
Diagnostic Grade (Green)
DDG2P
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesFetal anomalies
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesIntellectual disability
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesX-linked non-syndromic intellectual disability
Intellectual disability
non-syndromic X-linked intellectual disability
neurodevelopmental disorder
hereditary disease
X-linked intellectual disability
cask-related x-linked intellectual disability
hepatocellular carcinoma
breast cancer
neoplasm
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Ubiquitin carboxyl-terminal hydrolase 27
Deubiquitinase involved in innate antiviral immunity by mediating deubiquitination of CGAS and RIGI (PubMed:31534008, PubMed:32027733). Negatively regulates RIGI by mediating 'Lys-63'-linked deubiquitination of RIGI, inhibiting type I interferon signaling (PubMed:32027733). Also regulates 'Lys-63'-linked ubiquitination level of MDA5/IFIH1 (PubMed:32027733). Acts as a positive regulator of the cGAS-STING pathway by catalyzing 'Lys-48'-linked deubiquitination of CGAS, thereby promoting its stabilization (PubMed:31534008). Can reduce the levels of BCL2L11/BIM ubiquitination and stabilize BCL2L11 in response to the RAF-MAPK-degradation signal (By similarity). By acting on BCL2L11 levels, may counteract the anti-apoptotic effects of MAPK activity (By similarity)
USP27X · A6NNY8

Mean pLDDT
78.2/ 100
Confident
438 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0